Takeda, Amgen To Do New Phase III Trial Of Motesanib Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceuticals and U.S.-based Amgen have decided to make a new try to get their motesanib cancer drug through clinical trials. The drug designed to treat non-squamous non-small cell lung cancer, was pulled late last year when the death rate of participants in a Phase III trial became too high. The firms decided to try again after an independent monitoring committee recommended the move. An Amgen executive said the firm believes it has the correct patient population this time. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.